8-K: Coherus BioSciences Reports Positive 2024 Financial Results and Outlines Strategic Focus on Oncology

Coherus BioSciences reports a 4% increase in annual net revenue to $267.0 million for 2024, driven by UDENYCA and LOQTORZI growth, while strategically divesting other assets and focusing on its innovative oncology pipeline.

Summary

• Coherus BioSciences announced its financial results for the fourth quarter and full year 2024, highlighting a strategic shift towards becoming an innovative oncology company.
• Annual net revenue increased by 4% to $267.0 million in 2024, despite significant divestitures.
• UDENYCA net revenue saw a substantial increase of 62% year-over-year, reaching $206.0 million.
• LOQTORZI net revenue increased by 29% quarter-over-quarter, with full year sales of $19.1 million.
• The company is divesting UDENYCA, with the transaction expected to close late in the first quarter or early in the second quarter of 2025.
• Post-divestiture, Coherus expects to have approximately $250 million in cash, providing a cash runway exceeding two years.
• The company plans to reduce headcount by approximately 30% as part of organizational streamlining.
• Coherus anticipates multiple clinical data readouts from its innovative oncology pipeline in 2025 and 2026.
• Net income for the year ended December 31, 2024, was $28.5 million, compared to a net loss of $237.9 million in 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the increase in annual net revenue, the growth of UDENYCA and LOQTORZI sales, the expected cash infusion from the UDENYCA divestiture, and the promising clinical data from the oncology pipeline. However, the headcount reduction and the risks associated with the divestiture temper the overall sentiment.

Positives

• Annual net revenue increased by 4% to $267.0 million.
• UDENYCA net revenue increased significantly by 62% year-over-year.
• LOQTORZI sales are growing, with a 29% increase in net revenue quarter-over-quarter.
• The UDENYCA divestiture will provide a substantial cash infusion of approximately $250 million.
• The company expects a cash runway exceeding two years, funding the development pipeline through key data catalysts.
• Net income for the year ended December 31, 2024, was $28.5 million, a significant improvement from the net loss in 2023.
• The Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L HCC showed promising results with an overall response rate of 38% and complete responses of 17.2%.

Negatives

• Net revenue for the fourth quarter of 2024 decreased $37.4 million primarily due to the company's divestiture of CIMERLI and YUSIMRY.
• Cost of goods sold increased for UDENYCA and LOQTORZI in 2024, including $14.1 million in charges for the write-down of UDENYCA inventory that did not meet acceptance criteria.
• The company is reducing headcount by approximately 30%.

Risks

• The UDENYCA divestiture is subject to shareholder approval and other closing conditions, and may not occur as expected.
• The company's future financial results and performance could be affected by unforeseen liabilities or expenses related to the UDENYCA divestiture.
• Clinical drug development involves inherent risks and uncertainties.
• The company faces risks related to its competitive position and the regulatory approval process.
• The company's results for the fiscal period ended December 31, 2024, are preliminary and subject to change upon completion of the audited financial statements.

Future Outlook

Coherus projects post-UDENYCA-close cash of approximately $250 million and cash runway projections exceeding two years, past key data readouts expected in 2026. The company will focus on maximizing LOQTORZI revenue and advancing its innovative oncology pipeline.

Management Comments

• 2024 represents our transformation into an innovative oncology company, culminating in the agreement to divest UDENYCA, said Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• In 2025, we will be sharply focused on maximizing the revenue potential for LOQTORZI while advancing the development of our pipeline, including our first-in-class IL-27 antagonist, casdozokitug, and our CCR8-targeting antibody, CHS-114, in combination with LOQTORZI.
• Upon the completion of the UDENYCA divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million, continued Mr. Lanfear.
• These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.

Industry Context

Coherus's strategic shift towards oncology and divestiture of non-core assets reflects a broader trend in the biopharmaceutical industry where companies are focusing on core therapeutic areas and streamlining operations to improve profitability and fund innovative research. The company's focus on immuno-oncology aligns with the growing importance of these therapies in cancer treatment.

Comparison to Industry Standards

• Coherus's UDENYCA, a biosimilar of Amgen's Neulasta, competes in the biosimilar market against companies like Viatris and Sandoz.
• The 62% year-over-year growth in UDENYCA net revenue indicates a strong market position compared to its competitors.
• LOQTORZI, a PD-1 inhibitor, competes with established players like Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
• The designation of LOQTORZI as the only treatment with Preferred status in NPC by the NCCN gives it a competitive advantage.
• Coherus's focus on innovative immuno-oncology pipeline assets like casdozokitug and CHS-114 positions it to compete with companies developing next-generation cancer therapies.

Stakeholder Impact

• Shareholders will benefit from the increased focus on oncology and the potential for future growth.
• Employees will be affected by the headcount reduction of approximately 30%.
• Patients may benefit from the development of new cancer therapies.
• Customers will continue to have access to UDENYCA and LOQTORZI.
• Suppliers may be affected by the changes in the company's product portfolio.

Next Steps

• Complete the UDENYCA divestiture, expected late in the first quarter or early in the second quarter of 2025.
• Maximize the revenue potential of LOQTORZI.
• Advance the development of the company's innovative oncology pipeline, including casdozokitug and CHS-114.
• Report Phase 1 monotherapy biopsy data as well as CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.
• Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025.
• Report first data for Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC in Q2 2026.
• File the Annual Report on Form 10-K with the SEC.

Key Dates